降钙素阈值预测MEN2A基因携带者甲状腺髓样癌及其临床反应
该回顾性研究纳入106例MEN2A基因携带者,评估术前降钙素(CTN)对甲状腺髓样癌(MTC)诊断和生化治愈(ER)的预测价值。bCTN>12.60 ng/L识别MTC的敏感性94.4%、特异性74.3%;bCTN<28.25 ng/L预测ER的特异性95.5%、敏感性76.8%。术前bCTN在12.6–28.3 ng/L的携带者术后完全缓解概率很高。
要点
- bCTN>12.60 ng/L识别MTC的敏感性94.4%、特异性74.3%。
- bCTN<28.25 ng/L预测ER的特异性95.5%、敏感性76.8%。
- bCTN<28.25 ng/L和无淋巴结转移是ER的独立预测因素。
核心结论
- MEN2A基因携带者术前bCTN在12.6–28.3 ng/L时,术后获得完全生化与结构缓解的概率很高。
- 即使已存在小的甲状腺内MTC,该概率仍高,且独立于RET胚系突变类型。
研究设计与样本
- 回顾性评估前瞻性维护数据库,纳入1993–2024年意大利三级转诊中心接受手术并随访的106例基因携带者。
主要发现
- 最常见突变为RET V804M(36/106,34.3%),其次为634密码子突变(17/106,16.2%)。
- MTC患者较CCH患者RET筛查和手术时年龄更大,术前bCTN和sCTN水平更高。
- 中位随访6.8年,24/106(22.9%)出现不完全反应(IR);IR患者术前bCTN和sCTN高于ER患者。
关键数值与推荐
- bCTN>12.60 ng/L识别MTC的敏感性94.4%、特异性74.3%。
- bCTN<28.25 ng/L识别ER的特异性95.5%、敏感性76.8%。
- 多因素分析中,bCTN<28.25 ng/L和无淋巴结转移是ER的独立预测因素。
临床怎么用
- 对MEN2A基因携带者,术前bCTN可用于辅助判断MTC存在及术后完全缓解可能性。
- bCTN在12.6–28.3 ng/L的携带者术后完全缓解概率很高,可据此咨询。
局限性
- 回顾性单中心研究,样本量106例,结果需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In multiple endocrine neoplasia type 2 (MEN2), clinical management of gene carriers (GCs) is still debated, especially in MEN2A. We aimed to evaluate the predictive value of preoperative CTN for medullary thyroid cancer (MTC) diagnosis and excellent response (ER) in MEN2A GCs. METHODS: Retrospective evaluation from a prospectively maintained database of 106 GCs who underwent surgery and were followed up at an Italian tertiary referral center from 1993 to 2024. RESULTS: The most common mutation was RET V804M (36/106, 34.3%), followed by mutations at the 634 codon (17/106, 16.2%). Median age at surgery was 39 years. Eighty-six (81.1%) patients had MTC, while 20 patients (18.9%) had C-cell hyperplasia (CCH) alone. Patients with MTC were older than CCH ones both at RET screening and surgery and showed higher preoperative bCTN and sCTN levels. Values of bCTN > 12.60 ng/L identified MTC patients with a sensitivity of 94.4% and specificity of 74.3%. Incomplete response (IR) was observed in 24/106 (22.9%) patients during a median follow-up of 6.8 years. Patients with IR had higher preoperative bCTN and sCTN levels than patients with ER. bCTN < 28.25 ng/L identified patients with ER with a specificity of 95.5% and sensitivity of 76.8%. In multivariate analysis, bCTN < 28.25 ng/L and the absence of lymph node metastases were independent predictive factors of ER. CONCLUSION: GCs with a preoperative bCTN between 12.6 and 28.3 ng/L have a very high probability of achieving complete biochemical and structural remission after surgery, even when a small intrathyroidal MTC is already present and independently from the RET germline mutation.
引用
- Prete A, Matrone A, Romei C, et al. Calcitonin thresholds for prediction of medullary thyroid carcinoma and its clinical response in MEN2A gene carriers. J Clin Endocrinol Metab. 2026. PMID: 41689466. doi:10.1210/clinem/dgag041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。